Company intelligence / Profile preview

AmeriCann

Freetown, Massachusetts, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

AmeriCann reported four consecutive quarters of positive net income and record fiscal year-end results as of January 2023[4]. However, recent financial data shows trailing twelve-month earnings of -US$2.38 million on revenue of US$799.18 thousand, with a market cap of US$2.44 thousand as of December 31, 2024[2].

Therapeutic areas: NeurologyOther
Industry: Agriculture & AgTech

Partnerships

1906 (cannabis product brand partnership at Massachusetts Cannabis Center)

Beyond the preview

Go deeper on AmeriCann.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmeriCann.

Explore the full profile